Skill Guide

Real-world data integration (FAERS, EudraVigilance, VigiBase, EHR data)

The technical and analytical process of extracting, transforming, standardizing, and synthesizing adverse event reports and electronic health records from disparate global pharmacovigilance databases and EHR systems into a unified, queryable dataset for drug safety signal detection and benefit-risk assessment.

This skill directly enables the proactive identification of safety signals, significantly reducing regulatory risk and accelerating post-market surveillance timelines. It transforms fragmented, raw data into strategic intelligence that informs labeling changes, risk management plans, and ultimately protects patient safety and company assets.

1 Careers

1 Categories

8.8 Avg Demand

20% Avg AI Risk

How to Learn Real-world data integration (FAERS, EudraVigilance, VigiBase, EHR data)

Focus on: 1) Understanding the data structure and official query interfaces of each individual database (e.g., FAERS ASCII data files, EudraVigilance EVDAS online analysis). 2) Learning foundational coding for parsing XML/JSON from VigiBase and flat files from FAERS, using Python (pandas) or R. 3) Mastering the MedDRA (Medical Dictionary for Regulatory Activities) terminology hierarchy (PT, HLT, HLGT, SOC) for coding adverse events.

Move to practice by building a small-scale pipeline to compare report counts for a single drug across two databases. Common mistakes include: ignoring duplicate case reports within and across systems, failing to standardize drug names to a common vocabulary (e.g., using WHO-ATC or RxNorm), and underestimating the volume of unstructured 'narrative' text in EHR data. Use a cloud database (BigQuery, Snowflake) to manage growing data volume.

Master this at the strategic level by architecting a validated, enterprise-level data integration platform that ensures data lineage and audit trails for regulatory submission. Design probabilistic record linkage algorithms to match de-identified cases across EHR and spontaneous report databases. Mentor teams on signal detection methodologies (e.g., MGPS, PRR) applied to the integrated dataset, and present integrated analyses to regulatory agencies (FDA, EMA).

Practice Projects

Beginner

Project

FAERS-to-MedDRA Analysis for a Single Drug

Scenario

Analyze quarterly FDA Adverse Event Reporting System (FAERS) data for a specific, well-known drug (e.g., a statin) to identify its top 5 reported adverse events by frequency.

How to Execute

1) Download the latest quarterly FAERS ASCII data package from the FDA website. 2) Write a Python script using pandas to parse the 'DRUG' and 'REAC' files, joining them on case ID. 3) Filter for your target drug by its 'drugname' or 'ndc' field. 4) Map the reported 'pt' (preferred term) codes to MedDRA to group similar events and count frequencies, producing a summary table.

Intermediate

Project

Cross-Database Signal Comparison Pipeline

Scenario

A product safety team suspects a new drug may have a hepatic safety signal. You are tasked with creating a report that compares reporting rates for liver injury terms between FAERS, EudraVigilance, and VigiBase for the last 2 years.

How to Execute

1) Programmatically query EudraVigilance via EVDAS (or its offline download) and VigiBase via VigiLyze (requiring proper access credentials). 2) Build a pipeline that extracts counts for a defined SMQ (Standardised MedDRA Query) for 'Drug-related hepatic disorders' across all three sources. 3) Normalize the counts by estimating patient exposure (e.g., using IMS/IQVIA sales data for denominator). 4) Create a visualization comparing reporting ratios (e.g., Proportional Reporting Ratio) side-by-side for the three databases.

Advanced

Case Study/Exercise

Integrating EHR and Spontaneous Reports for a Benefit-Risk Assessment

Scenario

During an advisory committee meeting preparation, you must argue that a drug's cardiovascular risk observed in spontaneous reports is confounded by underlying disease. You need to integrate real-world EHR data to provide context on background rates and comorbidities.

How to Execute

1) Use an EHR data network (e.g., FDA's Sentinel, TriNetX, or an internal hospital network) to extract the incidence rate of the cardiac event of interest in a patient population matching the drug's indication, *without* the drug exposure. 2) Use natural language processing (NLP) on unstructured EHR notes to extract comorbidities not captured in structured fields. 3) Perform a disproportionality analysis on the spontaneous report database (FAERS) for the event. 4) Synthesize the findings into a single, cohesive analysis showing the spontaneous report signal *in context* of the higher baseline risk from EHR data, requiring expertise in epidemiology and data visualization.

Tools & Frameworks

Software & Platforms

Python (pandas, PyMedTerminology)R (openFDA, tidyverse)SQL (PostgreSQL, BigQuery, Snowflake)SAS (for legacy FDA submissions)Tableau/Power BI (for integrated dashboards)EVDAS (EudraVigilance Data Analysis System)VigiLyze (Uppsala Monitoring Centre portal)

Python and R are primary for data wrangling and analysis. SQL is essential for managing and querying large, integrated datasets in cloud data warehouses. SAS remains required for some regulatory deliverables. EVDAS and VigiLyze are the portals for direct, structured access to EudraVigilance and VigiBase data, respectively.

Data Standards & Methodologies

MedDRA (Medical Dictionary for Regulatory Activities)ICD-10/ICD-11WHO-ATC (Anatomical Therapeutic Chemical) ClassificationOHDSI Common Data Model (CDM) for EHRFDA Sentinel CDMProbabilistic Record Linkage (e.g., using Fellegi-Sunter model)

MedDRA is the universal language for coding adverse events. WHO-ATC standardizes drug names. The OHDSI and Sentinel CDMs are critical frameworks for transforming raw, heterogeneous EHR data into a standardized format for analysis, enabling multi-site studies.

Analysis Frameworks

Disproportionality Analysis (PRR, ROR, MGPS)Standardised MedDRA Queries (SMQs)Signal Detection Algorithms (e.g., BCPNN)Bayesian Meta-Analysis for integrating multiple data sources

Disproportionality analysis is the core statistical method for signal detection in spontaneous reports. SMQs provide pre-defined groupings of MedDRA terms for complex medical concepts. Bayesian methods are used at the advanced level to formally combine evidence from different data sources with different biases.

Interview Questions

Answer Strategy

The interviewer is assessing your architectural thinking and awareness of real-world data messiness. Strategy: Outline the ETL (Extract, Transform, Load) process clearly, then name specific, non-obvious challenges. Sample Answer: 'I'd design a pipeline using Python to ingest FAERS XML and EHR claims CSVs into a staging SQL database. The core transformation would map all drugs to WHO-ATC and all events/conditions to ICD-10/ MedDRA codes. The three major challenges are: 1) Patient/Case Identity: Linking a spontaneous report case to a specific EHR patient is impossible without a shared key, so we must analyze them as separate but correlated populations. 2) Temporal Misalignment: FAERS report dates are imprecise, while EHR data is timestamped; aligning exposure windows requires making and documenting assumptions. 3) Outcome Definition: A 'hospitalization for MI' in an EHR claim is a billing code, while in FAERS it's a narrative text; creating a unified, valid definition for analysis requires NLP and clinical adjudication.'

Answer Strategy

This behavioral question tests your applied experience and business acumen. Strategy: Use the STAR method (Situation, Task, Action, Result), focusing on the technical integration *you* performed and the tangible outcome. Sample Answer: 'In my previous role, a signal for pancreatitis emerged in EudraVigilance for our diabetes drug (Situation). My task was to assess if this was a true drug effect (Task). I built a pipeline comparing the reporting rate in EudraVigilance to FAERS, and then integrated EHR data from a research network to look at the incidence in diabetic patients with common comorbidities (gallstones, alcoholism). The analysis showed the EHR background rate was high and the spontaneous report signal was within expected range after adjusting for these confounders (Action). I presented this integrated analysis to our regulatory affairs team, who used it in a successful briefing document to the FDA, avoiding a premature label change and focusing our resources on a confirmed risk (Result).'